CliffBio
small molecule

CAYSTON

AZTREONAM

Loss of exclusivity—loss of exclusivity
CompanyGilead Sciences →See this company's full patent-cliff portfolio

Drug detail

Brand nameCAYSTON
Active ingredientAZTREONAM
Strength75MG/VIAL
Dosage formFOR SOLUTION
RouteINHALATION
ModalitySmall molecule
FDA approvalFebruary 2010
Marketing statusRX

More from Gilead Sciences

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.